Ivemend

Active Ingredient(s): Fosaprepitant Dimeglumine
FDA Approved: * September 5, 2019
Pharm Company: * TEVA PHARMS USA INC
Category: Nausea & Vomiting

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Ivemend Overview

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008[1] and by the European Medicines Agency (EMA) on January 11 of the same year.[2] See also Aprepitant Casopitant L-733,060 Maropitant Vestipitant References ^ "Drugs.com, FDA Approve...

Read more Ivemend Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fosaprepitant

Recent Ivemend Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Fosaprepitant Dimeglumine
  • Capsule: 125mg, 40mg, 80mg, 80mg + 125mg
  • Emulsion: 130mg/18ml (7.2mg/ml)
  • For Suspension: 125mg/kit
  • Injection: 130mg, 150mg/vial
  • Powder: 115mg/vial, 150mg/vial
  • Solution: 125mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Fosaprepitant Dimeglumine or a similar ingredient: (4 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 12 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA